Review paper
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives
Volume: 14, Issue: 4, Pages: 367 - 383
Published: Jan 17, 2020
Abstract
Introduction: The discovery of new actionable oncogenic drivers has led to the development of effective antineoplastic targeted agents in advanced non-small cell lung cancer (NSCLC). While the role of inhibitors of the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) is widely acknowledged, other oncogenic drivers can be exploited as therapeutic targets.Areas covered: Our aim is to...
Paper Details
Title
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives
Published Date
Jan 17, 2020
Volume
14
Issue
4
Pages
367 - 383
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History